8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

✍ Scribed by Brümmendorf, T.; Guigay, J.; Mesía, R.; Trigo, J.; Keilholz, U.; Dittrich, C.; Kerber, A.; Picard, M.; Vermorken, J.

• Book ID: 121959258
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 72 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71608-8